ID: ALA511563

Max Phase: Preclinical

Molecular Formula: C22H16N4O

Molecular Weight: 352.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(-c2cnc3c(-c4ccnc5ccccc45)cnn3c2)cc1

Standard InChI:  InChI=1S/C22H16N4O/c1-27-17-8-6-15(7-9-17)16-12-24-22-20(13-25-26(22)14-16)18-10-11-23-21-5-3-2-4-19(18)21/h2-14H,1H3

Standard InChI Key:  FAOGJKJCGFIFLI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 352.40

Molecular Weight (Monoisotopic): 352.1324

AlogP: 4.62

#Rotatable Bonds: 3

Polar Surface Area: 52.31

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 3.45

CX LogP: 3.95

CX LogD: 3.95

Aromatic Rings: 5

Heavy Atoms: 27

QED Weighted: 0.48

Np Likeness Score: -1.01

References

1. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT..  (2008)  Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.,  18  (15): [PMID:18621530] [10.1016/j.bmcl.2008.06.052]

2. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR..  (2013)  Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.,  23  (11): [PMID:23639540] [10.1016/j.bmcl.2013.03.113]

Source

Source(1):

• Scientific Literature